GSK confirms £500 million UK investment, more to follow?
This article was originally published in Scrip
Executive Summary
Just one day after the UK budget confirmed that the long awaited "patent box" would slash corporation tax, GlaxoSmithKline has today confirmed it will indeed be investing £500 million in UK manufacturing. But while UK industry appears to believe that the patent box and yesterday's budget make the UK more competitive, they say there is still more to do to guarantee investment.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.